Halton v. Bayer Healthcare Pharmaceuticals | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Halton v. Bayer Healthcare Pharmaceuticals

Sort by

Viewing results 1‒25 of 300

LexPharmaceuticals sector
Bayer’s break-up looks inevitable Premium content
...The former Roche pharmaceuticals boss took on one of the most unenviable jobs in corporate Europe last June....
February 28, 2024
European companies
Activist investor Jeff Ubben to join Bayer’s supervisory board
...Alongside Ubben, Bayer nominated Nancy Simonian, the former CEO of US biotech company Syros Pharmaceuticals, and Lori Schechter, the former general counsel of US healthcare group McKesson, to join its supervisory...
February 29, 2024
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
Bayer AG
Bayer shares plunge after blood-thinning drug trial halted
...The abandoned asundexian trial “is a major setback for Bayer”, said Markus Manns, a portfolio manager and healthcare expert at Union Investment, Germany’s third-largest asset manager....
November 20, 2023
Biotech
US biotech fundraising boom ends 2-year deal drought
...Metagenomi, a pre-clinical group backed by Moderna and Bayer, priced its $94mn IPO last week at the bottom of its target range, and fell 31 per cent on its first day of trading on Friday....
February 12, 2024
InterviewBayer AG
New Bayer chief plans a radically different style to cut bureaucracy
...They produce prescription drugs against cancer, heart disease and other illness, over-the-counter healthcare products like Bepanthen cream as well as seeds and herbicides for farmers....
June 18, 2023
Bayer AG
Bayer shifts pharma focus away from ‘innovation unfriendly’ Europe
...Bayer has said it is shifting the focus of its pharmaceutical business to the US and away from Europe and the UK, where governments are making “big mistakes” in how they manage health budgets....
January 16, 2023
FT Live
Global Pharma and Biotech Summit
Driving life sciences innovation in a disrupted world
Tuesday, 5 NovemberIn-Person & Online Conference
Bayer AG
Activist investor Jeff Ubben urges Bayer to look for external CEO
...healthcare and crop science....
January 9, 2023
The FT ViewThe editorial board
The battle over European drug pricing
...The head of Bayer’s drugs business warned this week the German company was shifting its pharmaceutical arm’s focus to the US, and away from Britain and European countries that were making “big mistakes”...
January 19, 2023
Special ReportAsia-Pacific Innovative Lawyers
Challenge of Asia-Pacific complexity is the spur to its creativity
...Consider Rajah & Tann’s work for Bayer on the use of drones. The pharmaceutical and chemicals conglomerate uses drones to help farmers in south-east Asia access more accurate and useful weather data....
May 5, 2023
News in-depthDrug prices
Drugmakers demand big cut in Britain’s medicines levy
...Meanwhile, Germany’s Bayer in January said it was cutting jobs in Britain because of the UK medicines levy....
February 27, 2023
Kate Bingham
Britain is losing its chance to become a life sciences superpower
...The pharmaceutical giants AbbVie and Eli Lilly have pulled out of the UK’s pricing agreement with the NHS. Bayer’s pharmaceutical arm is reducing its UK footprint and cutting jobs....
January 24, 2023
Roe vs Wade
Demand for morning-after pill rises in US as abortion restrictions spread
...of pharmaceuticals for the Americas....
February 16, 2023
Drug prices
US drugmakers withdraw from NHS pricing agreement as costs soar
...AbbVie and Eli Lilly have withdrawn from the deal after the German conglomerate Bayer’s pharmaceutical chief executive told the Financial Times on Monday that it was reducing its UK footprint and cutting...
January 16, 2023
News in-depthDrug prices
Big pharma groups rejoin battle with governments on drug prices
...Bayer, which is headquartered in Germany, told the Financial Times it will shift the focus of its pharmaceutical business to the US, accusing Europe of being “very innovation unfriendly”....
January 24, 2023
News in-depthArtificial intelligence
DeepMind spin-off steps up effort to use AI to create new drugs
...Some in the medical sector are sceptical that AI drug discovery will fulfil its hype, pointing to the need to navigate strict regulations and integrate into dated healthcare systems....
December 3, 2022
FT Live
Innovative Lawyers Awards Asia-Pacific
Celebrating innovations from both law firms and in-house teams in the region
Thursday, 16 MayHong Kong
FirstFT
FirstFT: Recession fears cloud Davos
...Bayer shuns ‘innovation unfriendly’ Europe The German pharmaceutical company has said it is shifting the focus of its drugs business to the US and away from Europe, where governments are making “big mistakes...
January 16, 2023
Special ReportAsia-Pacific Innovative Lawyers
Practice of law: best practice in legal work
...Paul Hastings O: 6; L: 7; I: 7; Total: 20The firm advised South Korean pharmaceutical company SD Biosensor and South Korean private equity fund SJL Partners on the acquisition of US-listed pharmaceutical...
May 5, 2023
News in-depthBiotech
Revolutionary Crispr gene editing speeds from lab to treatment room
...Accordingly, big pharma groups like Pfizer, Bayer and Regeneron have taken note, forming partnerships with the pioneers....
August 19, 2022
News in-depthWar in Ukraine
Aid efforts struggle to contain Ukraine’s multiple health crises
...“Supply chains have broken down because of the fighting and there is an urgent need to get healthcare supplies to people under siege,” said Pasko, who is liaising with healthcare vendors, logistics companies...
March 13, 2022
War in Ukraine
Western drugmakers walk ethical tightrope over Russian ties
...of healthcare and the pharmaceutical sectors....
March 18, 2022
Bayer AG
Bayer to buy US start-up Vividion for up to $2bn
...Bayer’s pharmaceuticals business in 2020 generated 42 per cent of the group’s revenue but 52 per cent of its operating profit before exceptional items....
August 5, 2021
Coronavirus treatment
Mexico uses human trials as path to secure future Covid-19 vaccines
...The Russian Direct Investment Fund, the Kremlin’s state wealth fund that has financed the Gamaleya Institute’s Sputnik V vaccine, declined to comment on the Mexico trials but said approval by national healthcare...
October 26, 2020
News in-depthGSK PLC
GSK confident independence best treatment for consumer health unit
...Other rivals include consumer groups Procter & Gamble, Colgate, Reckitt Benckiser and Nestlé, and drugmakers Bayer and Sanofi, while cheaper private-label products also command a chunk of the market....
December 21, 2021
Covid-19 vaccines
Russia criticises Brazil’s rejection of Sputnik V vaccine
...Anvisa, the country’s healthcare and medicines watchdog, cited risks with Sputnik V and said there was not enough information about its safety, effectiveness and quality....
April 27, 2021
GSK PLC
GSK consumer chief plans deal spree after split from pharma
...Its three biggest rivals are also pharmaceutical companies — Johnson & Johnson, Bayer and Sanofi — but healthcare has been an area of growth for consumer goods companies such as Reckitt Benckiser and Procter...
June 11, 2021

Previous pagePage 1 of 12Next page